Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Edwards Lifesciences Corporation (EW) had Revenue of $1.53B for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$1.53B
Net Income	$333.20M
Cost of Goods Sold	$344.40M
Gross Profit	$1.19B
Operating Expenses	$1.12B
Operating Income	$411.20M
Non-Operating Income/Expense	$-11.00M
Pre-Tax Income	$400.20M
Normalized Pre-Tax Income	$447.30M
Income after Taxes	$335.90M
Income from Continuous Operations	$335.90M
Consolidated Net Income/Loss	$331.50M
Normalized Income after Taxes	$390.57M
EBIT	$411.20M
EBITDA	$449.30M
Weighted-Average Shares Outstanding (Basic)	587.00M
Weighted-Average Shares Outstanding (Diluted)	587.90M
Earnings per Share (EPS) (Basic)	$0.57
Earnings per Share (EPS) (Diluted)	$0.56
Balance Sheet Financials
Current Assets	$6.58B
Property, Plant, and Equipment	$1.73B
Long-Term Assets	$6.91B
Total Assets	$13.49B
Current Liabilities	$1.40B
Long-Term Debt	$598.00M
Long-Term Liabilities	$1.48B
Total Liabilities	$2.88B
Common Equity	$10.61B
Tangible Shareholders Equity	$7.66B
Shareholders Equity	$10.61B
Common Shares Outstanding	587.90M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$570.60M
Cash Flow from Investing Activities	$-86.80M
Cash Flow from Financial Activities	$-205.30M
Beginning Cash	$3.06B
End Cash	$3.29B
Increase/Decrease in Cash	$231.20M
Stock-Based Compensation	$77.70M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.68
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.05
Debt to Equity Ratio	0.06
Gross Margin	77.52%
Operating Margin	26.84%
EBIT Margin	26.84%
EBITDA Margin	--
Pre-Tax Profit Margin	26.12%
Profit Margin	21.75%
Free Cash Flow	$465.30M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	0.30
Receiveable Turnover	1.70
Days Sales in Receivables	53.02
Return on Equity	3.17%
Return on Tangible Equity	4.39%
Return on Assets	2.49%
Return on Investments	3.00%
Book Value Per Share	$18.04
Free Cash Flow per Share	$0.79
Operating Cash Flow per Share	$0.97

Data from Zacks Investment Research, Inc.